June 5, 2025 5:46pm

As I wrote this a.m., “hold-on the railings; uncle algo and his electronic trading dwarfs are “thirsting” for trading profits”

As the cell and gene therapy sector oscillated from a negative open to a barely positive close while investors have watched with a half-closed eye on various breadth indicators ever since May’s “bad breadth” month

Non-farms econ are slated for tomorrow/Friday’s release

Waiting for news from ASCO – to keep the sector’s upside viable

Always be vigilant and in-the-know concerning your portfolio … why you need RMi!

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.

I put hours of effort to create reporting, while leveraging my 40 years of operating. investigative and research experiences to analyze the key market-moving events and distill that into a cogent outlook.

 

Thursday, RegMed Investors’ (RMi) pre-open: hold-on the railings … https://www.regmedinvestors.com/articles/13947

Wednesday night’s RegMed Investors (RMi) Closing Bell: Gauging sector breadth… https://www.regmedinvestors.com/articles/13946

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Thursday: The Dow closed DOWN -108 points or -0.25%, the S&P closed DOWN -31.51 points or -0.53% while the Nasdaq closed DOWN -162.04 points or -0.83%

  • Today’s market stumbled and tumbled
  • The string of labor market data this week raises the stakes for May’s nonfarm payrolls reading. Economists polled are expecting the report to show a gain of 125,000 for the month, which would be 52,000 less than the previous month.

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • Jobless claims for last week came in at 247,000, an increase of 8,000 from the week before and more than the estimate of 236,000; after a previous estimate by ADP’s private sector payrolls rose by just 37,000 in May, coming in sharply below the forecast for 110,000.

Thursday’s advance/decline line opened with a negative 8 incliner, 24 decline and 3 flats ending with a positive close of 16 incliners, 15 decliners and 4 flats  

Metrics:  Thursday, the IBB was down -0.06%, the XBI was up +0.08% while the VIX was up +0.87 points or +4.94% at 18.48

 

Q2/25 – June – 4 positive closes

  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Thursdays Closing UP (10 of 16) 

  • Alnylam Pharmaceuticals (ALNY +$2.69 after Wednesday’s +$1.54, Tuesday’s -$0.81 and Monday +$1.53),
  • uniQure NV (QURE +$1.65 after Wednesday’s -$0.20 and Tuesday +$0.72),
  • Lenz Therapeutics (LENZ +$1.11 after Wednesday’s -$0.58, Tuesday +$0.47 and Monday’s -$0.04),
  • CRISPR Therapeutics (CRSP +$0.52),
  • Verve Therapeutics (VERV +$0.44 after Wednesday’s +$0.44),
  • Solid Biosciences (SLDB +$0.41 after Wednesday’s +$0.34 and Tuesday’s -$0.045),
  • Ultragenyx Pharmaceuticals (RARE +$0.30),
  • Sage Therapeutics (SAGE +$0.24),
  • Vericel (VCEL +$0.23 after Wednesday’s +$.60, Tuesday’s +$1.09 and Monday’s -$0.83),
  • Compass Therapeutics (CMPX +$0.19),

Flat (4)

  • bluebird bio (BLUE) P/E acquired
  • Sangamo Therapeutics (SGMO)
  • Precigen (PGEN)
  • Homology Medicine (FIXX)

Wednesday’s Closing DOWN (10 of 15): 

  • Regenxbio (RGNX -$1.72 after Wednesday -$0.05 after Tuesday -$0.22 after Monday +$1.50),
  • Moderna (MRNA -$1.15 after Wednesday -$0.54 after Tuesday +$0.67 after Monday’s +$0.49),
  • BioLife Solutions (BLFS -$0.53 after Wednesday +$0.65, Tuesday’s +$0.75 after Monday’s -$1.19),
  • Agenus (AGEN -$0.47 after Wednesday +$0.63, Tuesday’s +$0.88 and Monday’s +$0.07),
  • Blueprint Medicine (BPMC -$0.20 after Wednesday +$0.50, Tuesday’s -$0.24 and Monday +$26.44)
  • Beam Therapeutics (BEAM -$0.15 after Wednesday +$0.27 and Tuesday’s +$0.62),
  • AxoGen (AXGN -$0.10 after Wednesday -$0.46),
  • Intellia Therapeutics (NTLA -$0.09 after Wednesday -$0.02 and Tuesday +$0.53),
  • MiMedx (MDXG -$0.08 after Wednesday -$0.06),
  • Fate Therapeutics (FATE -$0.08),

 

The BOTTOM LINE: The cell and gene therapy sector reverses on Thursday with a barely positive close after Wednesday’s positive close – although slipping …

Following upsides on Tuesday and Monday) after its “napping and waking” in the May share pricing doldrums initiated by a sweetener of BPMC getting an acquired by BMY, MRNA regulatory approval and BNTX’s partnership with BMY.

  • Algos and electronic trading are “thirsting” to reap profits

 

As I also wrote, about June… Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

  • Although historically, June (in the past) has been a slow or weak month – I/we just saw a tremendous start (6/2) with partnership, acquisition and regulatory news 
  • Also, ASCO opens this month with probably a lot of news flow attracting attention of funds such as hedges and electronic traders.

There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

June ‘25: understand the “flow” …

  • 6/5 – Thursday closed positive with 16 positive, 15 negative and 4 flats
  • 6/4 – Wednesday closed positive with 18 positive, 13 negative and 4 flats
  • 6/3 - Tuesday closed positive with 24 positive, 8 negative and 3 flats
  • 6/2 - Monday closed positive with 25 positive, 7 negative and 3 flats

From the last week of May:

  • 5/30 – last Friday closed negative with 6 positive, 26 negative and 3 flats
  • 5/29 – Thursday closed positive with 24 positive, 10 negative and 1 flat
  • 5/28 – Wednesday’s closed negative with 7 positive, 26 negative and 2 flats
  • 5/27 – Tuesday closed positive with 21 positive, 11 negative and 3 flats
  • 5/26 – Monday market holiday

 

I usually write/say “electronic trading and uncle algo” slips in and out, back doors reaping sector disharmony and then pops right back for some profiteering.

  • What can I say, love ‘em, leave ‘em and welcome back to save the sector’s honor – “uncle algo and his electronic dwarfs.”
  • Algos and electronic trading, can’t do with them and can’t do without them <me>

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Thursday: Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) and Lenz Therapeutics (LENZ),
  • Wednesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Mesoblast (MESO)
  • Tuesday: Vericel (VCEL), CRISPR Therapeutics (CRSP) and Agenus (AGEN)
  • Monday: Blueprint Medicine (BPMC), Ultragenyx Pharmaceuticals (RARE) and Alnylam Pharmaceuticals (ALNY)

The worst three (3) in the session: 

  • Thursday: Regenxbio (RGNX), Moderna (MRNA) and BioLife Solutions (BLFS)
  • Wednesday: Lenz Therapeutics (LENZ), Moderna (MRNA) and AxoGen (AXGN)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX) and Blueprint Medicine (BPMC)
  • Monday: BioLife Solutions (BLFS), Vericel (VCEL) and Mesoblast (MESO)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.